WASHINGTON, DC – Supreme Court justices appeared uncertain on Tuesday that doctors and anti-abortion groups have standing to challenge the FDA’s current label for the commonly used abortion pill mifepristone.
The Court is tasked with deciding whether to uphold a Fifth Circuit decision reversing the FDA’s long-standing prescribing conditions for mifepristone. While the drug has been approved in the US for more than two decades, key label changes in 2016 and 2021 have allowed the pill to be distributed by mail and extended how late into pregnancy it can be taken by three weeks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.